Bio Medica Laboratories Ipo
Bio Medica Laboratories IPO Review & Key Points
Review:
IPO Lead Managers aka Merchant Bankers
Narnolia Financial Services Ltd.
| Name of the Company | Face Value (₹) | EPS basic (₹) | EPS Diluted (₹) | RONW (%) | P/E Ratio | NAV (₹) |
| Powerica Limited | 5 | 15.26 | 15.26 | 15.37 % | 24.45 | 99.76 |
| Listed Peers | ||||||
| Cummins India Limited | 2 | 72.15 | 72.15 | 26.45% | 64.13 | 272.78 |
| Kirloskar Oil Engines Limited | 2 | 33.71 | 33.60 | 15.85% | 43.24 | 212.60 |
| NTPC Green Energy Limited | 10 | 0.67 | 0.67 | 2.58% | 129.40 | 21.88 |
| Acme Solar Holdings Limited | 2 | 4.55 | 4.53 | 5.59% | 50.74 | 74.54 |
| Adani Green Energy Limited | 10 | 8.37 | 8.37 | 11.90% | 101.53 | 76.62 |
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹132 to ₹139 Per Share |
| Issue Size | Approx ₹52.43 Crores, 37,72,000 Equity Shares |
| Fresh Issue | Approx ₹47.19 Crores, 33,95,000 Equity Shares |
| Offer for Sale: | Approx ₹5.24 Crores, 3,77,000 Equity Shares |
| Issue Type | Book build Issue |
| IPO Listing | NSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,78,000 |
| Retail Maximum | 2 | 2,000 | ₹2,78,000 |
| S-HNI Minimum | 3 | 3,000 | ₹4,17,000 |
| S-HNI Maximum | 7 | 7,000 | ₹9,73,000 |
| B-HNI Minimum | 8 | 8,000 | ₹11,12,000 |
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | 36,000 Shares | 0.95% |
| NII Shares Offered | 17,55,000 Shares | 46.53% |
| Retail Shares Offered | 17,92,000 Shares | 47.51% |
| IPO Open Date: | May 21, 2026 |
| IPO Close Date: | May 25, 2026 |
| Basis of Allotment: | May 26, 2026 |
| Refunds: | May 27, 2026 |
| Credit to Demat Account: | May 27, 2026 |
| IPO Listing Date: | May 29, 2026 |
| IPO Bidding Cut-off Time: | May 25, 2026 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 91,80,001 | 99.99% |
| Promoter Holding Post Issue | 1,25,74,801 | -% |
| Purpose | Crores |
| Repayment of Loan | ₹7.25 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | ₹24.81 |
| General Corporate Purpose | ₹- |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹16.25 | ₹15.80 | ₹0.33 | ₹17.57 |
| 2024 | ₹15.34 | ₹11.69 | ₹2.50 | ₹19.53 |
| 2025 | ₹38.33 | ₹25.18 | ₹9.79 | ₹39.12 |
| Nov 2025 | ₹28.63 | ₹16.95 | ₹8.66 | ₹65.17 |
| KPI | Values |
| ROE: | 99.59% |
| ROCE: | 48.20% |
| EBITDA Margin: | 39.83% |
| PAT Margin: | 25.64% |
| Debt to equity ratio: | 1.02 |
| Earning Per Share (EPS): | ₹10.67 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 99.59% |
| Net Asset Value (NAV): | ₹16.05 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Zenotech Laboratories Limited | 0.92 | – | 6.01% | 15.76 | 5.61 Cr. |
| Shukra Pharmaceuticals Limited | 0.22 | 47.57 | 15.90% | 1.43 | 9.58 Cr. |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹184.81 | ₹154.97 | ₹32.10 | ₹251.58 |
| 2024 | ₹206.45 | ₹175.85 | ₹34.44 | ₹339.25 |
| 2025 | ₹322.58 | ₹261.43 | ₹28.13 | ₹455.49 |
| Dec 2025 | ₹236.50 | ₹186.96 | ₹38.69 | ₹561.34 |